Lab Product News
News

Scientists map the spread of deadliest ovarian cancer


Vancouver, BC – BC Cancer Agency researchers are providing critical insight into the invasive spread of the most malignant form of ovarian cancer in a landmark study, published this week in Nature Genetics. This is a first in mapping two distinct patterns of ovarian cancer cell migration in high grade serous ovarian cancer.

 

The discovery, led by Dr. Sohrab Shah, senior scientist at the BC Cancer Agency, associate Professor at the University of British Columbia, and Canada research chair in computational cancer genomics, was made possible through genomic sequencing techniques and novel software developed by his bioinformatics team at the BC Cancer Agency. The study was simultaneously published in Nature Methods. The scientists have answered key unknowns about how deadly ovarian cancers spread, and the composition of the cancer cell groups that have taken up residence within the patient’s abdomen.

 

The study reveals that many cancer cell types make up a patient’s tumour. This could explain why some cells are susceptible to treatment when others are resistant, leading to relapse. Also, cell type migration patterns from ovary to other abdominal sites identified that specific ovary sites contained many more cell types relative to others. These regions could pinpoint ‘gateways’ of cell migration to other abdominal sites.

 

Unlike most cancers that spread through the blood stream or lymph system, this study shows that high grade serous ovarian cancer cells have a unique opportunity to spread prolifically throughout the abdomen. In mapping the cell migration, Dr. Shah’s team shows how cells are able to settle and thrive in specific regions of the body causing widespread, life-threatening disease.

 

The migration maps were primarily determined in pre-treatment samples with one exception. Shah’s team studied one patient with multiple relapse specimens. Notably, only a subset of cancer cells present at diagnosis led to treatment resistance.

 

Next steps are to use the innovative techniques developed for this study to define cell migration maps from additional patients over time with a specific focus on determining which cells are resistant to treatment. This will allow researchers to build predictive tools to better inform future care.

 

This new understanding of how high grade serous ovarian cancer cells migrate within the patient’s body provides insight that could inform future treatment selection. These results indicate that some cancer cells may have had pre-existing properties of resistance prior to the patient taking any treatment. This could indicate that a patient requires a much more aggressive, multi-treatment approach from the start to prevent relapse.